VEGFA and rectal cancer: The addition of bevacizumab, a humanized, monoclonal antibody targeting VEGF-A, to chemoradiation in the neoadjuvant setting for non-metastatic rectal cancer has limited benefit, which may indicate escape mechanisms to bevacizumab treatment37,38.